继续医学教育

母乳低聚糖在婴幼儿临床中的应用及在中国的展望

  • 姜璐 ,
  • 蔡威
展开
  • 上海交通大学医学院附属新华医院(上海 200092)

收稿日期: 2023-05-29

  网络出版日期: 2023-07-05

Clinical applications of human milk oligosaccharides in infants

  • Lu JIANG ,
  • Wei CAI
Expand
  • Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China

Received date: 2023-05-29

  Online published: 2023-07-05

摘要

母乳低聚糖(HMOs)是母乳中特有的、含量丰富的复合碳水化合物,作为母乳中含量第三的成分逐渐受到国内外学者关注。随着分析技术和多组学的快速发展,HMOs的研究已经取得了长足发展,并在过去几年取得较大突破。然而,我们仍处于揭示HMOs作用及机制的初级阶段,现有的结论主要来自于国外的临床研究,且仍需要进一步通过高质量的随机临床试验进行验证,并考虑其在不同疾病、环境和人群中的有效性。文章主要针对近年来HMOs对婴幼儿肠道菌群发育、肠道健康、免疫系统发育和脑部发育在临床中的应用作一简述,并对未来HMOs在中国婴幼儿中的应用前景进行探讨。

本文引用格式

姜璐 , 蔡威 . 母乳低聚糖在婴幼儿临床中的应用及在中国的展望[J]. 临床儿科杂志, 2023 , 41(7) : 556 -560 . DOI: 10.12372/jcp.2023.23e0465

Abstract

Human milk oligosaccharides (HMOs) are unique and abundant complex carbohydrates in breast milk. As the third most abundant component in breast milk, they have gradually received attention from scholars both domestically and internationally. With the rapid development of analytical techniques and multiomics, the research field of HMOs has made great progress and made great breakthroughs in the past few years. However, we are still in the initial stage of revealing the role and mechanisms of HMOs. However, the conclusions are mainly from foreign clinical studies, and need to be further verified by high-quality randomized clinical trials. In addition, we need to consider its effectiveness in different diseases, environment, and populations. Here, we summarize the roles of HMOs in regulating gut microbiome development, intestinal health, immune system development, and brain development in infants. Additionally, we explore the potential future applications of HMOs in infants in China.

参考文献

[1] Weirich A, Hoffmann GF. Ernst Moro (1874-1951)-a great pediatric career started at the rise of university-based pediatric research but was curtailed in the shadows of Nazi laws[J]. Eur J Pediatr, 2005, 164(10): 599-606.
[2] Petschacher B, Nidetzky B. Biotechnological production of fucosylated human milk oligosaccharides: prokaryotic fucosyltransferases and their use in biocatalytic cascades or whole cell conversion systems[J]. J Biotechnol, 2016, 235: 61-83.
[3] Macfarlane GT, Steed H, Macfarlane S. Bacterial metabolism and health-related effects of galacto-oligosaccharides and other prebiotics[J]. J Appl Microbiol, 2008, 104(2): 305-344.
[4] Ward RE, Ni?onuevo M, Mills DA, et al. In vitro fermentability of human milk oligosaccharides by several strains of bifidobacteria[J]. Mol Nutr Food Res, 2007, 51(11): 1398-1405.
[5] Lawson MAE, O'Neill IJ, Kujawska M, et al. Breast milk-derived human milk oligosaccharides promote Bifidobacterium interactions within a single ecosystem[J]. ISME J, 2020, 14(2): 635-648.
[6] Korpela K, Costea P, Coelho LP, et al. Selective maternal seeding and environment shape the human gut microbiome[J]. Genome Res, 2018, 28(4): 561-568.
[7] Garrido D, Ruiz-Moyano S, Kirmiz N, et al. A novel gene cluster allows preferential utilization of fucosylated milk oligosaccharides in Bifidobacterium longum subsp. longum SC596[J]. Sci Rep, 2016, 6: 35045.
[8] Porro M, Kundrotaite E, Mellor DD, et al. A narrative review of the functional components of human breast milk and their potential to modulate the gut microbiome, the consideration of maternal and child characteristics, and confounders of breastfeeding, and their impact on risk of obesity later in life[J]. Nutr Rev, 2023, 81(5): 597-609.
[9] Korpela K, de Vos WM. Early life colonization of the human gut: microbes matter everywhere[J]. Curr Opin Microbiol, 2018, 44: 70-78.
[10] Korpela K, Salonen A, Hickman B, et al. Fucosylated oligosaccharides in mother's milk alleviate the effects of caesarean birth on infant gut microbiota[J]. Sci Rep, 2018, 8(1): 13757.
[11] Borewicz K, Gu F, Saccenti E, et al. Correlating infant fecal microbiota composition and human milk oligosaccharide consumption by microbiota of 1-month-old breastfed infants[J]. Mol Nutr Food Res, 2019, 63(13): e1801214.
[12] Bosheva M, Tokodi I, Krasnow A, et al. Infant formula with a specific blend of five human milk oligosaccharides drives the gut microbiota development and improves gut maturation markers: a randomized controlled trial[J]. Front Nutr, 2022, 9: 920362.
[13] Estorninos E, Lawenko RB, Palestroque E, et al. Term infant formula supplemented with milk-derived oligosaccharides shifts the gut microbiota closer to that of human milk-fed infants and improves intestinal immune defense: a randomized controlled trial[J]. Am J Clin Nutr, 2022, 115(1): 142-153.
[14] Caplan MS. Paediatrics: are human milk oligosaccharides the magic bullet for necrotizing enterocolitis?[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(7): 394-395.
[15] Vandenplas Y, ?o?nowska M, Berni Canani R, et al. Effects of an extensively hydrolyzed formula supplemented with two human milk oligosaccharides on growth, tolerability, safety and infection risk in infants with cow's milk protein allergy: a randomized, multi-center trial[J]. Nutrients, 2022, 14(3): 530.
[16] Eiwegger T, Stahl B, Schmitt J, et al. Human milk--derived oligosaccharides and plant-derived oligosaccharides stimulate cytokine production of cord blood T-cells in vitro[J]. Pediatr Res, 2004, 56(4): 536-540.
[17] Masi AC, Embleton ND, Lamb CA, et al. Human milk oligosaccharide DSLNT and gut microbiome in preterm infants predicts necrotising enterocolitis[J]. Gut, 2021, 70(12): 2273-2282.
[18] Good M, Sodhi CP, Yamaguchi Y, et al. The human milk oligosaccharide 2'-fucosyllactose attenuates the severity of experimental necrotising enterocolitis by enhancing mesenteric perfusion in the neonatal intestine[J]. Br J Nutr, 2016, 116(7): 1175-1187.
[19] Xiao L, van De Worp WR, Stassen R, et al. Human milk oligosaccharides promote immune tolerance via direct interactions with human dendritic cells[J]. Eur J Immunol, 2019, 49(7): 1001-1014.
[20] Puccio G, Alliet P, Cajozzo C, et al. Effects of infant formula with human milk oligosaccharides on growth and morbidity: a randomized multicenter trial[J]. J Pediatr Gastroenterol Nutr, 2017, 64(4): 624-631.
[21] Zhang JY, Zhou SM, Wang SH, et al. Risk factors for cow's milk protein allergy in infants: a multicenter survey[J]. Zhongguo Dang Dai Er Ke Za Zhi, 2020, 22(1): 42-46.
[22] Sprenger N, Odenwald H, Kukkonen AK, et al. FUT2-dependent breast milk oligosaccharides and allergy at 2 and 5 years of age in infants with high hereditary allergy risk[J]. Eur J Nutr, 2017, 56(3): 1293-1301.
[23] Gold MS, Quinn PJ, Campbell DE, et al. Effects of an amino acid-based formula supplemented with two human milk oligosaccharides on growth, tolerability, safety, and gut microbiome in infants with cow's milk protein allergy[J]. Nutrients, 2022, 14(11): 2297.
[24] 裴景君. 母乳营养成分与早产儿脑发育的研究进展[J]. 中国当代儿科杂志, 2019, 21(6): 607-612.
[25] Foster JA, Lyte M, Meyer E, et al. Gut microbiota and brain function: an evolving field in neuroscience[J]. Int J Neuropsychopharmacol, 2016, 19(5): pyv114.
[26] Bode L. The functional biology of human milk oligosaccharides[J]. Early Hum Dev, 2015, 91(11): 619-622.
[27] Lin AE, Autran CA, Szyszka A, et al. Human milk oligosaccharides inhibit growth of group B Streptococcus[J]. J Biol Chem, 2017, 292(27): 11243-11249.
[28] Oliveros E, Ramirez M, Vazquez E, et al. Oral supple-mentation of 2'-fucosyllactose during lactation improves memory and learning in rats[J]. J Nutr Biochem, 2016, 31: 20-27.
[29] Berger PK, Plows JF, Jones RB, et al. Human milk oligosaccharide 2'-fucosyllactose links feedings at 1 month to cognitive development at 24 months in infants of normal and overweight mothers[J]. PLoS One, 2020, 15(2): e0228323.
[30] Alderete TL, Autran C, Brekke BE, et al. Associations between human milk oligosaccharides and infant body composition in the first 6 mo of life[J]. Am J Clin Nutr, 2015, 102(6): 1381-1388.
文章导航

/